ANR funded project
Atom Probe Tomograpy of 3-D nanoelectronic devices: Innovative meThods in reconstrUction and quantitative analysis DEvelopment
Project duration : 48 months
Today to fulfill the requirements of the « more Moore » approach in microelectronics, 3-D architectures are being developed along with new materials. Shrinking device dimensions mean that the control of dimensions and compositions during manufacture is an extremely important challenge for the microelectronic industry.
Atom Probe Tomography is a unique characterisation technique that allows the analysis of this new type of device both in terms of morphology and composition in three dimensions at the atomic scale. The APTITUDE project aims to develop analysis protocols and 3D reconstruction algorithms for atom probe that are not yet available for the complex structures encountered in nanoelectronic devices. The principal goals of this projet are the improvement of sample preparation protocols, the correlative use of electron- and atom-probe- tomography and the conception of new methods of 3-D reconstruction. The aim is to correct the reconstruction artefacts and obtain quantitative composition measurements whilst being able to define the detection limits (background noise, statistical noise…). At first, these algorithms will be developed at the GPM, then tested by the CEA-LETI on microelectronic structures issued from the sub-20nm development programmes of STMicroelectronics and finally integrated by CAMECA in a commercial package. APTITUDE is a project that fulfils the requirements for the thematic axis n°1 of the Nanotechnology and Nanosystems P2N call. It is an industrial research project that will comport two stages in coherence with the development of an intermediate and final commercial offering at 2 and 4 years. The APTITUDE project will bring together the following partners: 1. CEA-LETI Laboratoire d’Electronique et de Technologie de l’Information ; CEA 2. GPM Groupe de Physique des Matériaux ; UMR 6634 CNRS 3. CAMECA CAMECA SAS ; 4. STM STMicroelectronics
European funded Project- FP7
Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility
Project duration : February 2013 – March 2018
NanoAthero aims to demonstrate the preliminary clinical feasibility of the use of nanosystems for targeted imaging and treatment of advanced atherothrombotic disease in humans. NanoAthero offers a unique opportunity by combining in-depth knowledge of nanocarrier bioengineering and production with state-of-the-art expertise in imaging and treatment of cardiovascular patients providing a full framework of 16 partners within one collaborative European consortium. The NanoAthero project gathers together chemists, engineers, pharmacists, biologists, toxicologists, ethicists and clinical key leaders from RTOs, hospitals, SMEs and a large pharmaceutical company around on central theme: prove that the benefit of the use of nanoparticle technologies can be measured in a clinical setting. The reasoning behind the consortium can be highlighted by the general following questions:
- Can local delivery of a drug with a nanosystem change the balance between therapeutic and adverse effects thereby permitting the safe use of a drug already on the market or to be on the market?
- Can we treat vulnerable plaques with a nanosystem?
- What are pathological events in atherosclerosis that a nanosystem could detect with medical imaging?